DrugBiological
Tagraxofusp clinical trials
Also written SL-401 and Elzonris.
- studies test it
- 17
- open now
- 7
- in phase 3
- 0
- first study started
- 2014
Keep track of what changes. Save the tagraxofusp studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 10
- Phase 2
- 14
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 12
Stemline Therapeutics, Inc. (5) · M.D. Anderson Cancer Center (4) · Karen Ballen, MD (1) · City of Hope Medical Center (1) · Joshua Zeidner (1) · French Innovative Leukemia Organisation (1) · University of Kansas Medical Center (1) · Stanford University (1)
Often tested with
Tested in the same studies.
Venetoclax (5) · Azacitidine (4) · Decitabine (1) · Pacritinib (1)
Studies
Open first, then newest update. How each study uses tagraxofusp is read from its arms, and is right about nine times in ten.
Testing it · 17
- Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmRecruitingPhase 2M.D. Anderson Cancer CenterNCT04216524Written as Tagraxofusp-erzs
- Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT06498973Written as Tagraxofusp-erzs
- Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating AgentsRecruitingPhase 2Joshua ZeidnerNCT05442216Written as Tagraxofusp
- Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm PatientsRecruitingPhase 2French Innovative Leukemia OrganisationNCT07007052Written as Tagraxofusp
- Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedRecruitingEarly Phase 1University of Kansas Medical CenterNCT06414681Written as Tagraxofusp
- Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLRecruitingPhase 1/2Stanford UniversityNCT06561152Written as Tagraxofusp
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and VenetoclaxRecruitingPhase 1/2Jacqueline Garcia, MDNCT07148180Written as Tagraxofusp
- A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyActive, not recruitingPhase 2Stemline Therapeutics, Inc.NCT06456463Written as Tagraxofusp
- Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)Active, not recruitingPhase 1Karen Ballen, MDNCT05233618Written as Tagraxofusp
- Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic SyndromesActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT05038592Written as Tagraxofusp-erzs
- Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT05032183Written as Tagraxofusp-erzs
- Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid LeukemiaTerminatedPhase 2Gruppo Italiano Malattie EMatologiche dell'AdultoNCT04342962Written as tagraxofusp
- Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)CompletedPhase 1/2Stemline Therapeutics, Inc.NCT02268253Written as Tagraxofusp Injection
- SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete RemissionTerminatedPhase 1/2Stemline Therapeutics, Inc.NCT02270463Written as Tagraxofusp-erzs
- Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaCompletedPhase 1/2Stemline Therapeutics, Inc.NCT02113982Written as Tagraxofusp
- Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell TransplantTerminatedPhase 2M.D. Anderson Cancer CenterNCT04317781Written as Tagraxofusp-erzs
- SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaTerminatedPhase 1/2Stemline Therapeutics, Inc.NCT02661022Written as SL-401 7 µg/kg/day
Given in every arm · 3 — tagraxofusp is usual care beside what is tested
- SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)RecruitingPhase 1Dana-Farber Cancer InstituteNCT03113643Written as SL-401
- Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesRecruitingPhase 1Therapeutic Advances in Childhood Leukemia ConsortiumNCT05476770Written as Tagraxofusp
- Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid LeukemiaWithdrawnPhase 1Jonsson Comprehensive Cancer CenterNCT05720988Written as Tagraxofusp-erzs
Codes
What other systems call tagraxofusp · ClinicalTrials.gg INT000080
- MeSH (NLM) C000592123tagraxofuspConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8ZHS5657EHTAGRAXOFUSPConfirmed FDA, NLM, Wikidata
- RxNorm 2109055One source FDA
- Wikidata Q60666292tagraxofusp-erzsConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64769Tagraxofusp-erzsOne source FDA
- DrugBank DB14731One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592123 | tagraxofusp | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8ZHS5657EH | TAGRAXOFUSP | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2109055 | — | One source FDA |
| Wikidata | Q60666292 | tagraxofusp-erzs | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64769 | Tagraxofusp-erzs | One source FDA |
| DrugBank | DB14731 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.